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Ghrelin, a novel 28 amino acid peptide, was initially
purified from rat stomach (Kojima et al. 1999) and
localized to gastric oxyntic glands (Date et al. 2000a), the
hypothalamic arcuate nucleus (Kojima et al. 1999) and
kidney (Mori et al. 2000). In common with synthetic
growth hormone secretagogues (GHSs), ghrelin causes
growth hormone release in humans and rats following
either peripheral or central administration, and from
primary cultured pituitary cells (Kojima et al. 1999;
Takaya et al. 2000; Wren et al. 2000; Date et al. 2000b). In
rats, ghrelin has been found to stimulate food intake
(Wren et al. 2000; Nakazato et al. 2001), to induce adiposity
(Tschop et al. 2000) and to increase body weight (Tschop et
al. 2000; Nakazato et al. 2001), suggesting a possible role
in regulation of feeding behaviour and energy metabolism.
In addition, ghrelin has been recently reported to
stimulate gastric acid secretion and gastric motility in
anaesthetized rats (Masuda et al. 2000; Date et al. 2001).
The latter observation suggests that ghrelin may regulate
gastrointestinal function. 
Pancreatic exocrine secretion is controlled physiologically
by both the autonomic nervous system and a number of
brain–gut peptides. Among these peptides, cholecystokinin
(CCK), secretin and cocaine- and amphetamine-regulated
transcript peptide (CART) have been reported to
stimulate pancreatic secretion (Chey, 1993; Cowles et al.
2001), whereas neuropeptide Y and somatostatin serve as
inhibitors (Mulholland et al. 1991; Chey, 1993). The present
study was performed to examine the effect of ghrelin on
pancreatic exocrine function in anaesthetized rats. The
present authors sought to (1) demonstrate an in vivo
inhibitory effect of ghrelin on exocrine pancreatic
secretion stimulated by CCK, 2-deoxy-D-glucose (2-DG),
or bethanechol; and (2) determine the in vitro effects of
ghrelin on amylase release from purified pancreatic acini
and pancreatic lobules. 
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1. The role of ghrelin in the regulation of pancreatic protein secretion was investigated in vivo
using anaesthetized rats with pancreatic ductal cannulas, and in isolated pancreatic acinar cells
and pancreatic lobules in vitro.
2. In vivo, pancreatic protein output stimulated by CCK-8 (400 pmol kg_1 h_1) was dose-
dependently inhibited by continuous ghrelin infusion (1.2 and 12 nmol kg_1 h_1) by 45 ± 8 and
84 ± 7 %, respectively. 
3. In rats with acute subdiaphragmatic vagotomy, ghrelin (12 nmol kg_1 h_1) significantly
inhibited CCK-stimulated pancreatic protein secretion by 75 ± 18 %.
4. Infusion of ghrelin (12 nmol kg_1 h_1) abolished pancreatic protein secretion caused by the
central vagal stimulant 2-deoxy-D-glucose (75 mg kg_1), whereas bethanechol-stimulated
pancreatic protein output was inhibited by only 59 ± 7 %.
5. In vitro, ghrelin (10_11–10_7 M) produced no change in basal amylase release from dispersed,
purified acinar cells. Co-incubation of ghrelin (10_11–10_7 M) with CCK-8 (10_10 M)
demonstrated no inhibition of CCK-stimulated amylase release from dispersed acini. In
contrast, ghrelin (10_9–10_7 M) dose-dependently inhibited amylase release from pancreatic
lobules exposed to 75 mM potassium.
6. Our results show that (1) ghrelin is a potent inhibitor of pancreatic exocrine secretion in
anaesthetized rats in vivo and in pancreatic lobules in vitro; and (2) the actions of ghrelin are
indirect and may be exerted at the level of intrapancreatic neurons.
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METHODS
Materials
Rat ghrelin peptide was obtained from Phoenix Pharmaceuticals
(Mountain View, CA, USA). CCK-8 was purchased from Research
Plus, Inc. (Bayonne, NJ, USA). Bethanechol, 2-deoxy-D-glucose,
potassium chloride, N-2-hydroxyethylpiperazine-N fi-2-ethanesulfonic
acid (Hepes), bovine serum albumin (BSA), soy bean trypsin inhibitor
(SBTI), ketamine and xylazine were obtained from Sigma (St Louis,
MO, USA). PE10 and PE50 polyethylene tubing was purchased from
Becton Dickinson (Sparks, MD, USA). Infusion pumps and thermal
barriers were obtained from Harvard Apparatus, Inc. (South Natic,
MA, USA). Collagenase was obtained from Boehringer Mannheim
(Mannheim, Germany). Nitex nylon mesh (150 µm) was obtained
from Tetko, Inc. (Kansas City, MO, USA). The amylase assay kit was
purchased from Pharmacia Upjohn (Kalamazoo, MI, USA). The
protein assay kit was obtained from Bio-Rad laboratories (Hercules,
CA, USA).
In vivo studies
Animal preparation. Male Sprague-Dawley rats (200–250 g)
obtained from Harlan (Indianapolis, IN, USA) were used for all
experiments. Experimental protocols were reviewed and approved
by the University Committee on Use and Care of Animals of the
University of Michigan. Animals were cared for under pathogen-free
guidelines and housed at constant ambient temperature with
alternating light–dark cycles of 12 h. They were permitted free
access to water and standard rodent laboratory chow. They were fasted
overnight, with continued access to water, prior to experiments. 
On the morning of the experiment, rats were anaesthetized with
intramuscular injection of a mixture of xylazine and ketamine (13
and 87 mg (kg body weight)_1, respectively). Supplemental doses
were used every 2 h as needed to maintain adequate anaesthesia. An
intravenous cannula was placed into the right external jugular vein
for infusion of 0.9 % NaCl (1 ml h_1) and other chemicals. Through an
upper midline laparotomy, the duodenum was elevated and the
bile–pancreatic duct isolated as it entered the posterior duodenum.
Through a small incision, a polyethylene cannula (PE10) was
advanced into the bile–pancreatic common duct and was secured in
place with fine silk suture. A second polyethylene cannula (PE50)
was placed into the duodenum and its tip secured proximal to the
ampulla for infusion of previously harvested bile–pancreatic juice.
The abdominal wound was covered with a saline-moist gauze and the
rats were maintained at 37 °C with a thermal barrier. At the end of
experiments, animals were killed by CO2 inhalation and cervical
dislocation.
Pancreatic secretion study. Secreted bile–pancreatic juice was
collected for 45 min prior to starting the experiments to allow for
stabilization of flow following surgical manipulation. Bile–
pancreatic secretions were collected over 15 min periods. Volume was
recorded and aliquots assayed for protein content. Previously
collected bile–pancreatic juice was re-infused via the duodenal
cannula at the rate of 1.2 ml h_1. Protein measurements were made
using the Bio-Rad protein assay kit. 
CCK-8 stimulation. CCK-8 was infused continuously at a rate of
400 pmol kg_1 h_1 for 90 min. Preliminary studies determined that
this produced submaximal stimulation of pancreatic secretion.
Infusions of synthetic rat ghrelin (1.2 or 12 nmol kg_1 h_1) were
begun 15 min before CCK-8 administration and continued for the
remainder of the experiment. 
2-DG stimulation. 2-DG was dissolved in saline and administered as
a bolus intravenous injection at the end of the basal collection period.
Ghrelin infusion (12 nmol kg_1 h_1) was started 15 min before 2-DG
injection and continued for the remaining time of the experiment. 
Bethanechol stimulation. Bethanechol was dissolved in saline and
administered as a continuous intravenous infusion beginning at the
end of the basal collection period. Ghrelin infusion (12 nmol kg_1 h_1)
was begun 15 min before the bethanechol infusion and continued for
the rest of the experiment. 
Subdiaphragmatic vagotomy. Through a midline laparotomy, the
oesophagus was exposed. Subdiaphragmatic vagal trunks were
exposed halfway between the diaphragm and the gastric cardia and
both anterior and posterior trunks were transected.
Dispersed acini studies
Preparation of acinar cells. Preparation of dispersed rat pancreatic
acini was performed according to Williams et al. (1978). Briefly, rats
that had been fasted overnight were killed by CO2 inhalation, and the
pancreata were removed and placed in a Petri dish containing fresh
Krebs–Ringer buffer (KRB) solution consisting of (mM): 110 NaCl,
0.5 CaCl2, 1.1 MgCl2, 4.7 KCl, 0.55 Na2HPO4, 32.5 NaHCO3,
22 glucose, 2 glutamine, 0.1 mg ml_1 soybean trypsin inhibitor and
1 % (v/v) Eagle’s minimal essential amino acids, equilibrated with 5 %
CO2–95 % O2, adjusted to pH 7.4. After fat and lymphatic tissue were
trimmed away, each pancreas was digested with collagenase,
mechanically dispersed, and passed through a 150 µm mesh nylon
cloth. Acini were purified by centrifugation at 50 g for 3 min in KRB
solution containing 4 % BSA, and resuspended in incubation buffer
that consisted of Hepes buffered Ringer (HRB) solution containing
(mM): 127 NaCl, 1.28 CaCl2, 0.55 MgCl2, 4.7 KCl, 0.55 Na2HPO4,
10 Hepes, 11 glucose, 2 glutamine, 1 % (v/v) Eagle’s minimal essential
amino acids, 0.1 mg ml_1 soybean trypsin inhibitor and 10 mg ml_1
BSA, oxygenated with 100 % O2, and adjusted to pH 7.4. 
Amylase assay. Acini were pre-incubated at 37 °C with minimal
shaking for 60 min, followed by treatment with different agonists in
1 ml aliquots in polystyrene vials for the indicated times. Acini were
then pelleted. The acinar cells contained within the pellet were lysed
with a sonicator for 15 s. Amylase content in both the pellet and the
supernatants was determined using the Phadebas reagent and
expressed as a percentage of total cellular amylase content.
Pancreatic lobule studies
Pancreatic lobules, containing intrapancreatic nerve terminals and
islets in addition to exocrine cells, were prepared by the method of
Scheele & Palade (1975). Fasted rats were killed by CO2 inhalation
and pancreata were removed. After trimming away peripancreatic
fat and lymph nodes, the pancreatic tissue was divided into
4 mm w 5 mm lobular units; lobules were placed in Krebs–
Henseleit–bicarbonate (KHB) solution containing (mM): 110 NaCl,
1.8 CaCl2, 1.1 MgCl2, 4.7 KCl, 1.1 Na2HPO4, 25 NaHCO3, 25 Hepes,
11 glucose, 2 glutamine, 0.1 mg ml_1 soybean trypsin inhibitor, and
1 % (v/v) Eagle’s minimal essential amino acids, equilibrated with 5 %
CO2–95 % O2, and adjusted to pH 7.4. Lobules were allowed to
recover for 30 min at 37 °C. Lobular tissues were then exposed to the
agonist with or without the presence of graded concentrations of
ghrelin for 30 min. The medium was then aspirated, diluted 1:10 and
assayed for amylase. To the remaining tissue, 1 ml KHB was added
and the tissue was homogenized. Tissue homogenates were then
assayed for amylase. Amylase released was expressed as the
percentage of total tissue content.
Statistical analysis
Data were expressed as multiples of basal secretion. The results are
expressed as means ± S.E.M. A two-way analysis of variance
(ANOVA) was used to analyse differences between treatment
groups. Integrated protein output was calculated by cumulative
protein secretion during the time in which both ghrelin and agonists
were infused. Student’s unpaired t test was used to analyse data from
integrated protein secretion, volume and amylase output, and from
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dispersed acinar cell and pancreatic lobule preparations. Differences
were considered significant when P values were less than 0.05.
RESULTS
Effects of ghrelin on basal pancreatic secretion
Basal secretion was averaged from three 15 min
collections of bile–pancreatic juice prior to the application
of tested agents. The volume of basal secretion averaged
0.33 ± 0.02 ml per 15 min (n = 6). Basal pancreatic
protein secretion averaged 3.2 ± 0.8 mg h_1. Basal
amylase release was 3.7 ± 0.5 U min_1. Ghrelin infusion
(12 nmol kg_1 h_1) had no significant effect upon basal
secretory volume, protein or amylase outputs.
Effects of ghrelin on CCK-stimulated pancreatic
secretion
CCK-8 was infused at a rate of 400 pmol kg_1 h_1, which
was chosen to stimulate submaximal pancreatic secretion
(Schonfeld et al. 1989). Pancreatic protein output increased
significantly above basal levels by 15 min, reaching peak
values at 45 min, and remained significantly elevated for
the duration of the study (Fig. 1). The average volume of
bile–pancreatic juice increased from 0.32 ± 0.03 to
0.38 ± 0.04 ml per 15 min (n = 6, P < 0.05). Ghrelin was
infused at two doses (1.2 and 12 nmol kg_1 h_1), beginning
15 min before initiation of CCK-8 infusion. These doses of
ghrelin were chosen based on the studies in which ghrelin
significantly increased food intake in rats (Tschop et al.
2000; Wren et al. 2000) or stimulated gastric acid secretion
(Masuda et al. 2000). Significant and dose-related inhibition
of CCK-8-stimulated protein secretion was observed
(Fig. 1). Ghrelin at 1.2 nmol kg_1 h_1 produced a 45 ± 8 %
inhibition of the integrated CCK-stimulated pancreatic
protein secretion (P < 0.05), while a dose of 12 nmol
kg_1 h_1 inhibited integrated pancreatic protein output
by 84 ± 7% (P < 0.01). CCK at a dose of 400 pmol kg_1 h_1
significantly increased amylase secretion from the basal
of 3.9 ± 0.6 U min_1 to the peak rate of 23.3 ± U min_1
(P < 0.05 vs. basal). CCK-stimulated amylase release was
dose-dependently inhibited by ghrelin. Infusion of
ghrelin at doses of 1.2 and 12 nmol kg_1 h_1 significantly
reduced CCK-stimulated amylase output to 15.6 ±
1.4 U min_1 (P < 0.05 vs. CCK alone) and 8.7 ± U min_1
(P < 0.05 vs. CCK alone), respectively. CCK-induced
increases in secretory volume were also inhibited by ghrelin
infusion. In rats administered 1.2 and 12 nmol kg_1 h_1
ghrelin, secretion volume remained unchanged after CCK
infusion, averaging 0.35 ± 0.03 and 0.34 ± 0.01 ml per
15 min, respectively.
Effects of ghrelin on CCK-stimulated pancreatic
secretion in rats with acute vagotomy 
When subdiaphragmatic vagotomy was performed
acutely, ghrelin (12 nmol kg_1 h_1) retained the ability to
inhibit CCK (400 pmol kg_1 h_1)-induced increase in
pancreatic protein secretion by 75 ± 18 % (P < 0.05,
n = 6; Fig. 2). 
Effects of ghrelin on 2-DG-stimulated pancreatic
secretion
2-DG is a well-characterized centrally acting vagal
stimulant (Becker et al. 1988; Putnam et al. 1989). Infusion
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Figure 1. Effect of ghrelin on CCK-stimulated
pancreatic protein secretion
Ghrelin (1.2 and 12 nmol kg_1 h_1) was infused from
45 to 150 min and CCK-8 (400 pmol kg_1 h_1) from 60
to 150 min. The protein content of pancreatic
secretion was measured at 15 min intervals. Data are
expressed as means ± S.E.M. For each group, n = 6
(two-way ANOVA, P < 0.01).
Figure 2. Effect of ghrelin on pancreatic protein
secretion stimulated by CCK-8 (400 pmol kg_1 h_1)
in acutely vagotomized rats
Subdiaphragmatic vagotomy was performed prior to
beginning measurements. Ghrelin (12 nmol kg_1 h_1)
was infused continuously from 45 to 150 min. CCK
infusion was begun at 60 min in both groups. For
both groups, n = 6 (two-way ANOVA, P < 0.05).
of ghrelin was begun 15 min before 2-DG administration
(75 mg kg_1) (Fig. 3). Ghrelin at 12 nmol kg_1 h_1 abolished
2-DG-stimulated pancreatic secretion. 
Effects of ghrelin on bethanechol-stimulated
pancreatic secretion
The effects of ghrelin on cholinergically stimulated
pancreatic secretion were studied by using bethanechol, a
muscarinic receptor agonist without significant nicotinic
receptor effect (Putnam et al. 1989). Bethanechol at an
infusion rate of 3 mg kg_1 h_1 stimulated pancreatic
protein secretions by 5 ± 0.9-fold at 45 min (n = 6,
P < 0.05; Fig. 4). Infusion of ghrelin at a rate of
12 nmol kg_1 h_1 decreased integrated bethanechol-
stimulated pancreatic protein secretion by 59 ± 7 %
(P < 0.05). 
In vitro effects of ghrelin
To test for a direct inhibitory effect of ghrelin on
pancreatic exocrine function, dispersed acinar cells were
incubated with various doses of the peptide in vitro.
Ghrelin alone produced no significant change in basal
amylase release (Fig. 5). Co-incubation of CCK-8 (10_10 M)
with various concentrations of ghrelin produced no
alteration in amylase release compared to that observed
with CCK-8 alone (Fig. 5).
Incubation of pancreatic lobules in a medium containing
elevated potassium (75 mM) significantly increased
amylase release. Ghrelin, at concentrations from 10_9 to
10_7 M, dose-dependently decreased amylase release from
pancreatic lobules that were exposed to potassium (Fig. 6). 
DISCUSSION
The present study supports the concept that ghrelin
inhibits pancreatic secretion via a mechanism involving
the intrapancreatic nervous system. This contention is
supported by the following six pieces of evidence:
(1) ghrelin significantly inhibited CCK-stimulated
pancreatic secretion in vivo; (2) ghrelin inhibited CCK-
stimulated pancreatic secretion in rats with acute
vagotomy; (3) continuous infusion of ghrelin abolished
pancreatic secretion stimulated by 2-DG; (4) pancreatic
secretion stimulated by bethanechol was only partially
attenuated by infusion of ghrelin; (5) ghrelin demonstrated
no direct effect on the basal and CCK-stimulated amylase
release in dispersed acinar cells; and (6) ghrelin blocked
potassium-induced amylase release from pancreatic
lobules in vitro.
Ghrelin is a novel 28 amino acid peptide secreted from the
endocrine cells of gastric mucosa (Kojima et al. 1999). It is
an endogenous ligand for the growth hormone secretagogue
(GHS) receptor, which has been demonstrated in both the
central nervous system and peripheral tissues (Howard et
al. 1996; Guan et al. 1997; Papotti et al. 2000). Whereas
ghrelin was initially identified as a growth-hormone-
releasing peptide, a broader array of actions have
recently been reported. Expression of ghrelin and its
related receptor, GHS receptor, in kidney indicates that
ghrelin may play an important role in the regulation of
renal function (Mori et al. 2000). Stimulation of food
intake and subsequent body weight gain have been
demonstrated in rats administered ghrelin either centrally
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Figure 3. Inhibition of 2-DG-stimulated
pancreatic protein secretion by ghrelin
Ghrelin (12 nmol kg_1 h_1) was infused from 45 to
150 min and 2-DG (75 mg kg_1) was given by
intravenous bolus injection at 60 min. The results are
expressed as means ± S.E.M. For each group, n = 4
(two-way ANOVA, P < 0.05).
Figure 4. Effect of ghrelin on bethanechol-
stimulated pancreatic protein secretion
Ghrelin (12 nmol kg_1 h_1) was infused from 45 to
150 min and bethanechol (3 mg kg_1 h_1) from 60 to
150 min. Protein output was measured in 15 min
intervals. The results are expressed as means ± S.E.M.
Each group contained six animals (two-way ANOVA,
P < 0.05).
or peripherally (Tschop et al. 2000; Wren et al. 2000;
Nakazato et al. 2001). In the gastrointestinal system,
ghrelin has been demonstrated to regulate gastric acid
secretion and gastric motility (Masuda et al. 2000; Date et
al. 2001). 
That ghrelin may be involved in regulation of digestive
processes is supported by the observation that ghrelin-
producing cells correspond to X/A-like endocrine cells in
the gastrointestinal tracts of rats and humans identified
by light and electron microscopic immunohistochemistry
and by in situ hybridization (Date et al. 2000a). Ghrelin
receptor (GHS receptor) mRNA has also been identified in
the gastrointestinal tract including stomach, small
intestine and pancreas (Guan et al. 1997; Date et al.
2000a). While the pancreas has been demonstrated to
express GHS receptor by RT-PCR (Guan et al. 1997), the
functional response to ghrelin has not previously been
reported. The present studies demonstrate that ghrelin is
a potent inhibitor for stimulated pancreatic protein
secretion in vivo. As a result of rapid degradation in serum,
relatively high doses are required during peripheral
administration of ghrelin to achieve concentrations
equivalent to postprandial blood levels (Tschop et al.
2000). The doses used in our studies correspond to those
reported by Tschop et al. (2000) and Wren et al. (2000) to
increase food intake in rats.
Regulation of pancreatic exocrine secretion occurs at
multiple levels, including the central nervous system,
pancreatic innervation, intrapancreatic neurons and via
receptors on pancreatic acinar cells. While ghrelin
inhibited pancreatic protein output in vivo, the effect was
indirect because ghrelin did not have an effect when
dispersed pancreatic acini were exposed to the peptide in
vitro. These in vitro studies strongly suggest that the
inhibitory actions of ghrelin are not mediated by direct
actions on the acinar cells. Similar indirect inhibitory
action on pancreatic secretions has been reported for
neuropeptide Y (NPY; Mulholland et al. 1991). Similar to
NPY, ghrelin appears to act on the intrapancreatic
neurons to inhibit pancreatic protein secretion.
Several recent reports suggest that ghrelin acts within
the central nervous system. Ghrelin up-regulates the
expression of c-fos, NPY and agouti-related protein
(AGRP) genes in hypothalamus (Hewson & Dickson,
2000; Kamegai et al. 2000; Nakazato et al. 2001) and c-fos
mRNA expression in dorsomotor nucleus of the vagus
(Date et al. 2001). Stimulation of gastric secretion by
ghrelin administered by intracerebroventricular injection
is mediated by direct central activation of a central vagal
mechanism (Date et al. 2001). Three observations from the
present study support the idea that the actions of ghrelin
on pancreatic secretion are directed at the level of intra-
pancreatic neurons. First, ghrelin abolished pancreatic
protein secretion stimulated by 2-DG, a centrally acting
vagal stimulant, but only partially inhibited pancreatic
protein secretion stimulated by CCK or bethanechol.
Secondly, vagotomy failed to reverse the inhibitory effects
of ghrelin on CCK stimulation of pancreatic secretion.
Thirdly, ghrelin dose-dependently decreased amylase
release stimulated by depolarizing concentration of KCl
in pancreatic lobules.
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Figure 5. In vitro effects of ghrelin on CCK-8-
stimulated amylase release from dispersed rat
acinar cells
Acinar cells were incubated with varying
concentrations of ghrelin (10_11–10_7 M) in the
presence or absence of CCK-8 (10_10 M). The results for
amylase are calculated as a percentage of total
amylase content. The results are expressed as
means ± S.E.M. from four separate experiments.
Figure 6. Effect of ghrelin co-incubation on
potassium chloride (75 mM)-stimulated amylase
release (multiple of control) from pancreatic
lobules
The results are expressed as means ± S.E.M. for five
separate experiments. * P < 0.05 vs. KCl; ** P < 0.01
vs. control.
In summary, the present study has demonstrated that
ghrelin is a potent inhibitor of pancreatic exocrine
secretion in anaesthetized rats. The study supports the
conclusions that (1) the actions of ghrelin are indirect; and
(2) ghrelin may affect intrapancreatic neurotransmission
as a mechanism of action.
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